JK08

Description

JK08 is an investigational medication currently being studied in clinical trials for various types of cancer, including colorectal cancer. It is being evaluated in Phase 1 trials to determine its safety, how the body processes it (pharmacokinetics), its effects on the body (pharmacodynamics), how the immune system reacts to it (immunogenicity), and whether it shows early signs of fighting the cancer (preliminary antitumor activity). These trials are designed to find the right dose and understand how patients respond to the drug. It is administered as a subcutaneous injection once a week. The trials are open-label, meaning both the researchers and participants know who is receiving the drug. JK08 is being studied both on its own (monotherapy) and in combination with other cancer treatments, such as lenvatinib and pembrolizumab, in some trials. The trials are looking at patients whose cancer cannot be removed surgically (unresectable locally advanced) or has spread to other parts of the body (metastatic).

Mechanism of Action

The specific way JK08 works is still being investigated in clinical trials. It is being studied to see how it affects cancer cells and the body's response to cancer. The trials aim to characterize its mechanism of action as part of understanding its safety and potential effectiveness.

Side Effects

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials